The expression of B-2 microglobulin (B-2M) on tumor cells and their normal cell counterparts in 39 patients with renal cell carcinoma was studied and correlated to tumor stage and survival. The median survival time of patients with localized disease (stage I) whose tumors expressed B-2M was 10.2 years while the median survival time for patients whose tumors did not express B-2M was only 3.6 years (p < 0.001). For patients with more advanced disease (stages II, 111, IV) whose tumors expressed B-2M, median survival time was 3.6 years compared to 2.0 years in patients whose tumors did not express B-2M, a non-significant difference. It is suggested that the tumor cell membrane expression of B-2M may serve as an indicator of good prognosis in early renal cell carcinoma. ©1991 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.
CITATION STYLE
Levin, I., Kuperman, O., Goldstein, J., Neumann, L., Segal, S., Kaneti, J., … Klein, B. (1991). Cellular b-2 microglobulin expression as a prognostic indicator in renal cell carcinoma. Acta Oncologica, 30(8), 941–945. https://doi.org/10.3109/02841869109088247
Mendeley helps you to discover research relevant for your work.